EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer

The anti-HER2 antibody trastuzumab is standard care for advanced esophagogastric (EG) cancer with ERBB2 (HER2) amplification or overexpression, but intrinsic and acquired resistance are common. We conducted a phase 2 study of afatinib, an irreversible pan-HER kinase inhibitor, in trastuzumab-resista...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Sanchez-Vega, Francisco, Hechtman, Jaclyn F., Castel, Pau, Ku, Geoffrey Y., Tuvy, Yaelle, Won, Helen, Fong, Christopher J., Bouvier, Nancy, Nanjangud, Gouri J., Soong, Joanne, Vakiani, Efsevia, Schattner, Mark, Kelsen, David P., Lefkowitz, Robert A., Brown, Karen, Lacouture, Mario E., Capanu, Marinela, Mattar, Marissa, Qeriqi, Besnik, Cecchi, Fabiola, Tian, Yuan, Hembrough, Todd, Nagy, Rebecca J., Lanman, Richard B., Larson, Steven M., Pandit-Taskar, Neeta, Schöder, Heiko, Iacobuzio-Donahue, Christine A., Ilson, David H., Weber, Wolfgang A., Berger, Michael F., de Stanchina, Elisa, Taylor, Barry S., Lewis, Jason S., Solit, David B., Carrasquillo, Jorge A., Scaltriti, Maurizio, Schultz, Nikolaus, Janjigian, Yelena Y.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6368868/
https://ncbi.nlm.nih.gov/pubmed/30463996
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-18-0598
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados